You are here

TCT

 
 

Highly anticipated research on Abbott Vascular’s bioresorbable coronary stent was revealed over the weekend, and results were a bit underwhelming for cardiologists who hoped it would outperform metallic stents.

 
 - TCT Abbott
TCT 2016: Abbott’s bioresorbable heart stent not performing as expected

Highly anticipated research on Abbott Vascular’s bioresorbable coronary stent was revealed over the weekend, and results were a bit underwhelming for cardiologists who hoped it would outperform metallic stents.

Roundtable: Optimizing Your Structural Heart Disease Program
Expert Roundtable: Optimizing Your Structural Heart Disease Program

Have you ever wanted to be a fly on the wall when thought leaders in structural heart talk heart to heart about building their program, the challenges, the triumphs and the big picture, now is your chance, take a listen.

 - surgery
TCT.15: Polymer-free, drug-coated stent has superior outcomes in high bleeding risk patients undergoing PCI

Patients at high risk for bleeding who underwent PCI had better outcomes if they received a polymer-free umirolimus-coated stent compared with a bare-metal stent, according to a randomized, double blind trial.

 - Patient
TCT.15: Drug-coated balloon is superior to PTA in patients with peripheral artery disease

After two years of follow up, patients with peripheral artery disease who received a drug-coated balloon had significantly higher primary patency and a significantly lower rate of clinically driven target lesion revascularization compared with patients who received conventional percutaneous transluminal angioplasty (PTA).

 - conference speaker audience
TCT.15: Researcher explains trial that led to FDA notification of potential TAVR, SAVR issues

The lead author of a recent trial that led to an FDA notification of potential issues with bioprosthetic aortic valves reiterated that the findings related to neurologic events were preliminary and inconclusive.